Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta-analysis aimed at evaluating the comparative efficacy of BTK inhibitors in R/R CLL.
The addition of inotuzumab ozogamicin to bridging therapy led to high objective response rates and sustained survival in obe-cel recipients with B-cell ALL.
A donor-derived CAR T-cell therapy produced complete remissions, but survival was limited in relapsed/refractory T-cell lymphoma.
Stable disease was common in patients with CD123-positive, relapsed/refractory acute myeloid leukemia who were treated with AFM28.
James K. McCloskey II, MD, discusses the advantages of the oral formulation of decitabine plus cedazuridine for patients with MDS and CMML.
A small sample size from an analysis of the FELIX trial suggests consolidative SCT may not be needed after obe-cel treatment in relapsed/refractory B-ALL.
Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.
Rene Y. McNall-Knapp, MD, discusses the current treatment paradigm for pediatric and adult patients with NF1-associated PNs.
Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.
Panelists discuss how osimertinib monotherapy demonstrated robust progression-free survival and overall survival benefits in FLAURA, while FLAURA2 showed that adding chemotherapy to osimertinib further improved…
UCSF experts highlight leadership in innovative cancer research and education.
